Company news
Bionano Genomics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease
April 23, 2025
Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM
April 8, 2025
Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
March 31, 2025
Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect
March 24, 2025
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting
March 18, 2025
Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025
March 14, 2025
Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML
March 13, 2025
Bionano Announces Effective Date of Reverse Stock Split
January 21, 2025
Bionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss
January 13, 2025
Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results
January 12, 2025
Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia
January 6, 2025
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 2, 2025
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
December 30, 2024
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
December 22, 2024
Bionano Announces Presentations at the American Society of Hematology (ASH) Annual Meeting that Underscore OGM Utility Across Blood Cancer Research and Cell & Gene Therapy
December 9, 2024
Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress
November 12, 2024
Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024
November 6, 2024
Bionano Announces $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
October 30, 2024
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
October 30, 2024
Bionano Announces Publication Outlining Utility of OGM for Resolution of MYC Gene Rearrangements in Multiple Myeloma
October 23, 2024
Bionano Announces Preliminary 3Q 2024 Revenues and Cash
October 9, 2024
Bionano Adjourns Special Meeting of Stockholders to October 30, 2024
October 2, 2024
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
August 6, 2024
Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting
July 31, 2024
Bionano to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 7, 2024
July 30, 2024
Bionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma
July 22, 2024
Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 4, 2024
Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
July 1, 2024
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
June 19, 2024
Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
June 16, 2024
Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow
May 29, 2024
Bionano Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet
May 27, 2024
Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
May 20, 2024
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
May 8, 2024
Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
May 7, 2024
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
April 30, 2024
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
April 23, 2024
Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
April 10, 2024
Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 3, 2024
Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics
April 2, 2024
Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting
April 1, 2024
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
March 18, 2024
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System
March 6, 2024
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
March 4, 2024
Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024
February 27, 2024
Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway
February 27, 2024
Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
January 24, 2024
Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing
January 23, 2024
Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
January 22, 2024
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
January 18, 2024
Calls
The 5 newest of 24 calls. Every call is listed under its year.
- Bionano Genomics (NASDAQ:BNGO) Q2 2026 Earnings Call
Aug 10, 2026
Transcript - Bionano Genomics (NASDAQ:BNGO) Q1 2026 Earnings Call
May 13, 2026
Transcript - Bionano Genomics (NASDAQ:BNGO) Q4 2025 Earnings Call
Mar 23, 2026
Transcript - Bionano Genomics (NASDAQ:BNGO) Q3 2025 Earnings Call
Nov 13, 2025
Transcript - Bionano Genomics (NASDAQ:BNGO) Q2 2025 Earnings Call
Aug 14, 2025
Transcript
Decks
The 5 newest of 18 decks. Every deck is listed under its year.
- Investor Presentation (September 2026)
Investor deck · 28 slides · Sep 14, 2026
- Q2 2026 Earnings Presentation
Earnings · 15 slides · Aug 10, 2026
- Q1 2026 Earnings Presentation
Earnings · 14 slides · May 13, 2026
- Q4 2025 Earnings Presentation
Earnings · 17 slides · Mar 23, 2026
- Q3 2025 Earnings Presentation
Earnings · 13 slides · Nov 13, 2025